Modelling immunity in agent-based models

Gray Manicom, Emily Harvey, David Wu, Joshua Looker, Oliver Maclaren, Dion R.J. O’Neale · 2025

Read Modelling immunity in agent-based models by Gray Manicom, Emily Harvey, David Wu, Joshua Looker, Oliver Maclaren, Dion R.J. O’Neale (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2504-13706.txt.

Introduction

Gray Manicom and co-authors calibrate immunity inside agent based models of disease spread. Such models guide vaccine policy, but their immunity settings are tricky. Many vaccines leak: they cut risk per exposure rather than granting full armor. So the modeler's numbers must bend with exposure pressure and with the model's own rules.

The team first builds target immunity curves from real COVID data and immune studies. They then fit lean waning curves that hit those targets inside simulations. Household spread tests link per attempt protection to the overall immunity seen. The method accounts for network shape and the code's spread rules, giving policy models a firmer base.

Catalog record

CREATORGray Manicom, Emily Harvey, David Wu, Joshua Looker, Oliver Maclaren, Dion R.J. O’Neale
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE42 KB
VERSION1.0
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2504-13706

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Modelling immunity in agent-based models Gray Manicom, Emily Harvey, David Wu, Joshua Looker, Oliver Maclaren, Dion R.J. O’Neale Abstract 1 Summary Vaccination policies play a central role in public health interventions and models are often used to assess the effectiveness of these policies. Many vaccines are leaky, in which case the observed vaccine effectiveness depends on the force of infection. Within models, the immunity parameters required for agent-based models to achieve observed vaccine effectiveness values are further influenced by model features such as its transmission algorithm, contact network structure, and approach to simulating vaccination. We present a method for determining parameters in agent-based models such that a set of target immunity values are achieved. We construct a dataset of desired population-level immunity values against various disease outcomes considering both vaccination and prior infection from COVID-19. This dataset incorporates immunological data, data collection methodologies, immunity models, and biological insights. We then describe how we choose minimal parameters for continuous waning immunity curves that result in those target values being realized in simulations. We use simulations of the household secondary attack rates to establish a relationship between the protection per infection attempt and overall immunity, thus accounting for the dependence of protection from acquisition on model features and the force of infection. 2 Introduction Infectious diseases continue to pose significant challenges to global health, necessitating robust models to inform decision-making and evaluate intervention strategies. Central to these models is the accurate representation of immunity, which is dynamic due to factors such as waning over time and the emergence of new pathogen variants. Vaccination campaigns aim to develop herd immunity and mitigate the spread of diseases, making it critical to obtain reliable estimates of immunity from both vaccination and previous infections for incorporation into mathematical models. The force of infection is the rate at which susceptible individuals become infected in a given time window. Vaccine effectiveness (VE) measures how much that risk is reduced among vaccinated individuals in observational studies. However, many vaccines are leaky, and measures of vaccine effectiveness for leaky vaccines vary in different settings [ 1 , 2 ] . In particular, vaccine effectiveness measurements tend to decrease as the force of infection increases, with an explanation being that there may be more infection attempts on vaccinated individuals and thus a higher chance of being infected, even when the vaccine blocks certain infection attempts [ 3 ] . Thus, biological factors and non-pharmaceutical interventions, such as wearing masks or social distancing, that impact the force of infection may result in larger measurements of vaccine effectiveness. Likewise, in agent-based models of infectious diseases, infectious individuals may make multiple attempts to infect vaccinated susceptible individuals, and the number of these attempts per unit time is determined by the model’s transmission mechanism, force of infection, contact structure, implementation of non-pharmeceutical interventions, and other modelling assumptions. To state it simply, the model’s representation of VE depends on the model itself. Careful consideration must therefore be made in choosing the immunty parameters that will result in the desired VE being observed in model simulations. In particular, this means determining the relationship between the protection that immunity provides against each infection attempt and the overall immunity of the simulated population. Additionally, the immunity that leaky vaccines provide tends to wane over time, and so the protection against infection attempts and subsequent disease outcomes should also wane. Various approaches have been used to model leaky immunity for different models based on experimental data. In compartment models, this has been done by having a rate at which individuals move from a recovered state to a susceptible state [ 4 , 5 ] or by having different compartments for different levels of immunity over time [ 6 ] . In agent-based models, this has been done by changing the probability of individual agents entering different disease states, typically introducing new states for different levels of immunity [ 7 , 8 , 9 , 10 , 11 , 12 , 13 ] . The significance of this research is the demonstration of how vaccine effectiveness (VE) or immunity from previous infections, observed in epidemiological studies, can be accurately translated into model parameters, accounting for the complexities of how the immunity provided by leaky vaccines depends, in the real world and in simulations, on the force of infection and modeling assumptions. This makes the model more accurate, relevant and flexible for real-world applications. This paper describes a method for incorporating immunity against disease acquisition, symptoms, hospitalization, critical care, and death into an agent-based model, using COVID-19 as a case study. Immunity results from vaccination with one to four doses of the Pfizer vaccine with or without previous infection, giving nine classes of immunity for each disease outcome which wane over time. Unlike many agent-based models, which introduce new states where individuals may have fixed immunity levels for long periods, our approach represents immunity as a continuous time-dependent multiplier on the rate of infection. This continuous representation is advantageous for modelling scenarios with variable intervals between vaccinations and reinfections and accommodates different waning rates for various disease outcomes. To account for how vaccine effectiveness depends on modelling assumptions and the force of infection, we set up a series of numerical simulations to act as case-control studies, use these simulations to calculate the relationship between model parameters and vaccine effectiveness, and then determine the parameters that are needed to match target vaccine effectiveness values from the literature. To measure vaccine effectiveness in simulations, we run simplified numerical simulations of spread in disconnected households. We then use the household secondary attack rate (HSAR), which is the probability that a susceptible individual in a household gets infected when at least one other individual in that household gets infected [ 14 ] , to determine the parameter needed for ‘protection against acquisition per infection attempt’ to produce overall population-level vaccine effectiveness values for different infection pressures. This gives the model accuracy and flexibility when applied to real-world modelling scenarios, since different policy interventions and biological adaptations may result in the force of infection changing, which, in turn, changes the relationship between model parameters and the population-level immunity observed in simulations. In Subsection 2.1 we introduce one of the agent-based models used as part of the COVID-19 response in New Zealand. In Section 3 we describe the methods we use to acquire parameters for our model that produce realistic protection values. In Subsections 3.1 and 3.2 we overview the method and introduce notation. In Subsection 3.3 we construct a target dataset of immunity values based on a model fit to observed data, making adjustments based on biological insights, observed data, and modelling considerations. In Subsection 3.4 we provide the method for determining the parameters of logistic transition probability curves that can be incorporated into our model to achieve the target immunity values in simulations. Theoretical and numerical analysis is used to determine the how to fit model parameters to the target dataset with special attention paid to the relationship between the protection from acquisition per infection attempt and the cumulative protection. In Section 4 we show the results of this method, first by showing the target immunity values in Subsection 4.1 and then by showing the immunity

Read the complete text